By Fineline Cube 
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.
Rigerna’s Technology Platform
Rigerna, a pioneer in the siRNA field, has established the proprietary SRNA technology platform. This platform holds global intellectual property rights and encompasses core technologies such as delivery vectors, chemical modification, and sequence selection.
Clinical Progress
Rigerna’s lead candidate, RG002, for the treatment of kidney diseases like IgA Nephropathy (IgAN), has initiated Phase I clinical trials. This progress places Rigerna at the forefront globally and provides initial validation of the clinical potential of its technology platform.-Fineline Info & Tech